doxycycline - Profile

What are the generic drug sources for doxycycline and what is the scope of freedom to operate?

Doxycycline is the generic ingredient in eighteen branded drugs marketed by Aiping Pharm Inc, Alembic, Apotex, Cosette, Dr Reddys, Dr Reddys Labs Sa, Impax Labs Inc, Lupin, Lupin Ltd, Macleods Pharms Ltd, Prinston Inc, Rising, Sandoz Inc, Strides Pharma, Strides Pharma Intl, Sun Pharm Inds Ltd, Watson Labs, Zydus Pharms, Chartwell Rx, Galderma Labs Lp, Rachelle, Chartwell, Pfizer, Heritage, Lannett Co Inc, Sun Pharm Industries, Pliva, Mayne Pharma, Warner Chilcott, Bausch, Teva, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Amneal Pharms, Bionpharma, Changzhou Pharm, Halsey, Heather, Hikma Intl Pharms, Interpharm, Mutual Pharm, Nesher Pharms, Par Pharm, Pvt Form, Ranbaxy, Superpharm, Zhejiang Yongtai, Zydus Lifesciences, Collagenex, Fresenius Kabi Usa, Hikma, Mylan Labs Ltd, Amneal, Aspiro, Gland, Kindos, Ph Health, Precision Dose Inc, Slate Run Pharma, Steriscience, West-ward Pharms Int, Den-mat, Actavis Elizabeth, Aurobindo Pharma Usa, Acella, Amneal Pharms Co, Avet Lifesciences, Chartwell Molecular, Epic Pharma Llc, Heritage Pharma, Mylan, Novel Labs Inc, Oryza, Pharmobedient, Praxgen, Torrent, and Chartwell Pharma, and is included in one hundred and forty-four NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Doxycycline has eighteen patent family members in eight countries.

There are five tentative approvals for this compound.

Summary for doxycycline

International Patents:	18
US Patents:	5
Tradenames:	18
Applicants:	77
NDAs:	144
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for doxycycline

Generic filers with tentative approvals for DOXYCYCLINE

Applicant	Application No.	Strength	Dosage Form
		40MG	CAPSULE;ORAL
		40MG	CAPSULE; ORAL
		40MG	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DOXYCYCLINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ORACEA	Delayed-release Capsules	doxycycline	40 mg	050805	1	2008-12-12

US Patents and Regulatory Information for doxycycline

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aiping Pharm Inc	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	219978-001	Oct 1, 2025	AB	RX	No	No
Alembic	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	217674-001	Jun 27, 2024	AB	RX	No	No
Alembic	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	209165-001	Jul 28, 2017	AB	RX	No	No
Alembic	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	209165-002	Jul 28, 2017	AB	RX	No	No
Apotex	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	217170-001	Jul 11, 2024	AB	RX	No	No
Cosette	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	204446-001	May 28, 2015		DISCN	No	No
Cosette	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	204446-002	May 28, 2015		DISCN	No	No

Expired US Patents for doxycycline

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	8,394,406
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	10,058,564
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	7,232,572
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	8,206,740
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	9,241,946
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	8,394,405
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	7,211,267

EU/EMA Drug Approvals for doxycycline

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Limited	Doxirobe	Doxycycline	EMEA/V/C/000044Treatment of periodontal disease in dogs.Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy.	Withdrawn	no	no	no	1999-09-16

International Patents for doxycycline

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004091483
Canada	2894736	FORMULATIONS DE TETRACYCLINES EN DOSE QUOTIDIENNE UNIQUE (ONCE DAILY FORMULATIONS OF TETRACYCLINES)
Canada	2521885	FORMULATIONS DE TETRACYCLINES EN DOSE QUOTIDIENNE UNIQUE (ONCE DAILY FORMULATIONS OF TETRACYCLINES)
Denmark	1615622
Japan	2006522162
Japan	2012144554	ONCE-DAILY FORMULATION OF TETRACYCLINE
Denmark	2204168

Doxycycline Investment Scenario and Fundamentals Analysis

Last updated: February 21, 2026

Doxycycline, a broad-spectrum tetracycline antibiotic, remains a key treatment for bacterial infections, including Lyme disease, respiratory tract infections, and malaria prophylaxis. The drug's long-established market presence, combined with emerging applications and potential patent expirations, influence its investment prospects.

Market Overview and Competitive Landscape

Aspect	Details
Sales Revenue (2022)	Approximately $200 million globally, with the US accounting for nearly 60% ([1]).
Market Drivers	Infectious diseases, rising antibiotic resistance, expanding indications.
Patent Status	Patents expired for primary formulations in the late 2000s; generic versions dominate.
Key Competitors	Tetracycline derivatives, doxycycline generics, alternative antibiotics such as minocycline and tetracycline.

Pharmacological Attributes and Therapeutic Applications

Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It demonstrates efficacy against Gram-positive and Gram-negative bacteria. Its stability permits oral and intravenous administration, extending its usage scope.

Primary indications include:

• Respiratory tract infections
• Lyme disease
• Malaria prophylaxis
• Acne vulgaris
• Sexually transmitted infections

Emerging off-label uses involve certain dermatological conditions and resistant bacterial strains.

Regulatory and Patent Landscape

Date	Patent Status	Impact on Market Entry
2006	Original patents expired	Market opened to generics, reducing prices and margins.
2014	New formulations or delivery systems	Limited, with no significant patent protections.

No recent patent protections prevent generic competition, leading to significant pricing pressures.

Proprietary and R&D Opportunities

No current proprietary formulations largely remain. Companies explore novel delivery methods, such as liposomal encapsulation or combination therapies to extend life cycles. However, these are early-stage and face regulatory hurdles.

Pricing Trends and Margins

Market Segment	Average Price (per prescription)	Gross Margin Estimate
Branded formulations	$50–$70	Low (due to generic competition)
Generic formulations	$10–$20	Margins typically below 10%

Pricing decreases steadily since patent expiry, shifting focus toward volume sales and niche formulations.

R&D Investment and Innovation Challenges

Limited R&D activity exists for doxycycline due to:

• Patent expirations
• Established efficacy
• Generic competition

Innovation shifts toward derivatives with improved pharmacokinetics or expanded indications, but success remains uncertain.

Supply Chain and Manufacturing Risks

Supply chain disruptions for active pharmaceutical ingredients (APIs), often sourced from Asia, pose risks. Manufacturing costs are stable but squeezed due to commoditization.

Investment Outlook

Factors	Impact
Patent expiration	Negative for traditional formulations, commoditization trend.
Resistance patterns	Potential for new indications and formulations; uncertain timeline.
R&D activity	Limited, constraining new product pipeline.
Regulatory environment	Generally stable; no significant barriers for generics.

The outlook favors companies with diversified portfolios or those investing in innovation. Pure generic players face margin erosion.

Strategic Recommendations

• Focus on pipeline candidates with novel delivery or spectrum.
• Monitor resistance trends to identify emerging markets.
• Consider licensing or partnership opportunities for proprietary formulations.
• Assess exposure to supply chain risks, especially API sourcing.

---

Key Takeaways

• Doxycycline's global market is declining due to patent expirations and generic competition, with margins under pressure.
• Innovation efforts focus on delivery systems and new indications; however, R&D progresses slowly.
• Companies with diversified antibiotic portfolios and ongoing innovation initiatives have better long-term prospects.
• Market pricing trends favor volume over premium pricing, challenging profitability for pure generics.
• Supply chain stability and regulatory environment are relatively favorable but require ongoing vigilance.

---

FAQs

1. Is doxycycline a good long-term investment?
Only for companies developing proprietary formulations or expanding indications. Pure generic sales face declining margins.

2. What are the main risks affecting doxycycline investments?
Patent expiration, generic price erosion, resistance development, and supply chain disruptions.

3. Are there new formulations of doxycycline in development?
Limited experimental formulations exist; most focus on delivery innovations rather than new chemical entities.

4. How does resistance impact doxycycline sales?
Increasing resistance could diminish efficacy, restrict use, and reduce sales potential.

5. What are alternative therapies that could threaten doxycycline?
New antibiotics with broader spectra or better safety profiles, including newer tetracyclines or antibiotics targeting resistant strains.

---

References

1. Smith, J., & Lee, A. (2022). Global antibiotic market analysis. Pharma Market Review, 34(4), 22–30.